EVPM ICSR(s)		Individ	dual Case Safety	EudraVigilance			
General Information							
EudraVigilance Local Report Number			EU-EC-10013145442				
Sender Type			Regulatory authority				
Sender's Organisation			EEA Regulator				
Type of Report			Spontaneous				
Primary source country			European Economic Area				
Reporter's qualification			Non-Healthcare Professional				
Case serious?			Yes				
Patient							
Age Group			Age Group (as per reporter)			Sex	
18-64 Years						Male	
Reaction / Event							
MedDRA LLT			Duration		Outcome		Seriousness <sup>1</sup>
Thrombosis NOS			Fatal				death., other
Drug Information							
Role <sup>2</sup>	Drug		Duration	Dose	1	Jnits in Interval	Action taken
S	COVID-19 VACCINE JANSSEN (AD26.C COVID-19 VACCINE JANSSEN (AD26.C						
Drug In	formation (cont.)						
Info <sup>3</sup>	Drug		Indication			harm. Form	Route of Admin.
	COVID-19 VACCINE JANSSEN (AD26.COV2.S) COVID-19 VACCINE JANSSEN (AD26.COV2.S)		- N/A				

<sup>1</sup> Seriousness: death=results in death; life threat.=life threatening; hospital.=requires hospitalization/prolongation of hospitalization; disability=results in disability/incapacity; congen.=congenital anomaly/birth defect; other=other medically important information; (blank)=non-serious

<sup>2</sup> Drug role: S=suspect; C=concomitant; I=interacting; N=not administered

<sup>3</sup> Additional Information on Drug: 1=Counterfeit; 2= Overdose; 3=Drug taken by the father; 4=Drug taken beyond expiry date; 5=Batch and lot tested and found within specifications; 6=Batch and lot tested and found not within specifications; 7=Medication error; 8=Misuse; 9=Abuse; 10=Occupational exposure; 11=Off label use; (blank) = no additional information